Pharmaceutical Industry ‘Business With Disease’ Facing
Further Legal Challenges
A Judge in the Superior Court of New Jersey in the United
States, presiding over a class action lawsuit against the
pharmaceutical industry, has approved a master class action
complaint form that can be used by all plaintiffs who wish to
sue the pharma-cartel.
Click here to download a
copy in PDF format. |
Dying for Drugs

Empowered by Dr Rath’s consistent exposure of the pharmaceutical “business
with disease” Europe’s leading news magazine “Der
Speigel” was able to openly
and fearlessly criticise this industry without fear of threat of
a legal backlash - and now a mainstream television station in the UK
has taken up the torch.
At 8:30 pm on Sunday April 27th 2003, the terrestrial mainstream
TV station Channel 4 broadcast a documentary made by an independent
production
company with the title 'Dying for Drugs.' Every year, many new drugs
come to market which bring billions of pounds into the coffers of the
pharmaceutical industry, making Big Pharma the most profitable and
powerful business on earth.
This film investigates just how far drug companies are prepared to
go to get their drugs approved; what they will do to make sure they
get the prices they want and what happens when profits are put before
people.
Unsurprisingly, this broadcast has caused the pharmaceutical industry
a real headache in trying to preserve their image as a caring, ethical
business. Shortly after the program aired, the trade magazine Pharmaceutical
Marketing carried an article defending the ‘business with disease’ with
the usual platitudes. The article does, however, acknowledge that the
industry now has a huge crisis management issue on its hands.
As a result of the continuing information initiative undertaken by
Dr Rath and this Foundation, the genie is out of the bottle and there
is no going back. The pharmaceutical industry is now likely to have
a hard time convincing the public that its business model is beneficial
to their health rather than just lining the pockets of its shareholders.
|